WO2005026316A3 - Alphavirus vaccines - Google Patents

Alphavirus vaccines Download PDF

Info

Publication number
WO2005026316A3
WO2005026316A3 PCT/SE2004/001333 SE2004001333W WO2005026316A3 WO 2005026316 A3 WO2005026316 A3 WO 2005026316A3 SE 2004001333 W SE2004001333 W SE 2004001333W WO 2005026316 A3 WO2005026316 A3 WO 2005026316A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
alphavirus
deletion
vaccines
present
Prior art date
Application number
PCT/SE2004/001333
Other languages
French (fr)
Other versions
WO2005026316A2 (en
WO2005026316A8 (en
Inventor
Peter Liljestroem
Original Assignee
Bioption Ab
Peter Liljestroem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioption Ab, Peter Liljestroem filed Critical Bioption Ab
Publication of WO2005026316A2 publication Critical patent/WO2005026316A2/en
Publication of WO2005026316A3 publication Critical patent/WO2005026316A3/en
Publication of WO2005026316A8 publication Critical patent/WO2005026316A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to recombinant alphavirus vectors and expression of heterologous antigens therefrom in animal cells. Said vectors are characterized by having inter alia an alphavirus 3’-untranslated region (3’-UTR) comprising a deletion of non-essential nucleotides, suitably a deletion of at least 525 nucleotides. Recombinant alphavirus vectors of the present invention can be used for preparing antigenic compositions which can be administered as vaccines.
PCT/SE2004/001333 2003-09-15 2004-09-15 Alphavirus vaccines WO2005026316A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50263203P 2003-09-15 2003-09-15
US60/502,632 2003-09-15

Publications (3)

Publication Number Publication Date
WO2005026316A2 WO2005026316A2 (en) 2005-03-24
WO2005026316A3 true WO2005026316A3 (en) 2005-05-26
WO2005026316A8 WO2005026316A8 (en) 2005-07-21

Family

ID=34312409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2004/001333 WO2005026316A2 (en) 2003-09-15 2004-09-15 Alphavirus vaccines

Country Status (1)

Country Link
WO (1) WO2005026316A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310510B1 (en) * 2008-07-17 2015-05-06 Medigen, Inc. Idna vaccines and methods for using the same
EE05711B1 (en) 2009-10-07 2014-04-15 Tartu Ülikool Method and composition for the generation of conditionally lethal viral mutants and elimination of eukaryotic cell viability
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
EP3548625B1 (en) * 2016-12-05 2024-06-26 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
WO2024092346A1 (en) * 2022-11-04 2024-05-10 The University Of British Columbia Binary self-amplifying nucleic acid platform and uses thereof
WO2024133550A1 (en) * 2022-12-22 2024-06-27 Vector Biopharma Ag Eukaryotic self-amplifying system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
WO1998015636A1 (en) * 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
WO2002099035A2 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
WO1998015636A1 (en) * 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
WO2002099035A2 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGLUND P. ET AL: "Enhancing immune responses using suicidal DNA vaccines.", NATURE BIOTECHNOLOGY, vol. 16, June 1998 (1998-06-01), pages 562 - 565, XP055067450, DOI: doi:10.1038/nbt0698-562 *
FROLOV I. ET AL: "Cis-acting RNA elements at the 5' end of Sindbis virus genome RNA regulate minus- and plus- strand RNA synthesis.", RNA, vol. 7, 2001, pages 1638 - 1651 *
PFEFFER M. ET AL: "The Alphavirus 3'-Nontranslated Region: Size Heterogeneity and Arrangement of Repeated Sequence Elements.", VIROLOGY, vol. 240, no. 240, 1998, pages 100 - 108, XP004446027 *

Also Published As

Publication number Publication date
WO2005026316A2 (en) 2005-03-24
WO2005026316A8 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
EP1064024A4 (en) Vaccines against circovirus infections
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2006085983A3 (en) Viral adjuvants
AR041880A1 (en) IMMUNOGEN COMPOSITION
DE60117978D1 (en) MODIFYING THE HEPATITIS B NUCLEAR ANIMAL
WO2003082183A3 (en) Protein-based streptococcus pneumoniae vaccines
ATE397942T1 (en) ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
HK1044484A1 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
IL178917A0 (en) A method for preparing tc-83-derived alphaviral particles
JP2003528887A5 (en)
EP2441838A3 (en) Fusion proteins that contain natural junctions
WO2006020720A3 (en) Stable pegylated interferon formulation
ATE287947T1 (en) ORAL IMMUNIZATION BY USING TRANSGENIC PLANTS
WO2006073431A3 (en) Avipox recombinants expressing foot and mouth disease virus genes
WO2021154812A8 (en) Coronavirus vaccine formulations
CO6150189A2 (en) VACCINES FOR MALARIA
WO2004001051A3 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
WO2006060728A3 (en) Methods and compositions involving lcrv proteins
NO20050721D0 (en) HSP70 from Artherobacter
WO2013104995A3 (en) Compositions and methods for treating viral infections
WO2005026316A8 (en) Alphavirus vaccines
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens
WO2003040305A3 (en) Porcine adenovirus e1 and e4 regions
UA101385C2 (en) Immunological compositions comprising sulpholipo-cyclodextrin cyclodextrin (sl-cd) and saponin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69 1 EPC

122 Ep: pct application non-entry in european phase